Teva Remains Focused On Tardive Dyskinesia After Huntington’s Stumble

FDA's complete response letter for deutetrabenazine for treatment of chorea associated Huntington disease does not request additional clinical trials, and Teva said a filing timeline for tardive dyskinesia remains unchanged.